Prague Med. Rep. 2013, 114, 162-171

https://doi.org/10.14712/23362936.2014.18

25-hydroxyvitamin D3 Concentration in  Serum and Cerebrospinal Fluid of Patients with Remitting-relapse Multiple Sclerosis

Ali Moghtaderi1,*, G. H. Tamadon2, F. Haghighi1

1Department of Neurology, Zahedan University of Medical Sciences, Zahedan, Iran
2Department of Laboratory Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

References

1. Balabanova, S., Richter, H. P., Antoniadis, G., Homoki, J., Kremmer, N., Hanle, J., Teller, W. M. (1984) 25-hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. Klin. Wochenschr. 62(22), 1086–1090. <https://doi.org/10.1007/BF01711378>
2. Brown, J., Bianco, J. I., McGrath, J. J., Eyles, D. W. (2003) 1,25-dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci. Lett. 343(2), 139–143. <https://doi.org/10.1016/S0304-3940(03)00303-3>
3. Chen, S., Sims, G. P., Chen, X. X., Gu, Y. Y., Chen, S., Lipsky, P. E. (2007) Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179(3), 1634–1647. <https://doi.org/10.4049/jimmunol.179.3.1634>
4. Correale, J., Ysrraelit, M. C., Gaitán, M. I. (2009) Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132(Pt 5), 1146–1160. <https://doi.org/10.1093/brain/awp033>
5. Embry, A. F., Snowdon, L. R., Vieth, R. (2000) Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 48(2), 271–272. <https://doi.org/10.1002/1531-8249(200008)48:2<271::AID-ANA28>3.0.CO;2-O>
6. Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., McGrath, J. J. (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 29(1), 21–30. <https://doi.org/10.1016/j.jchemneu.2004.08.006>
7. Felgenhauer, K. (1974) Evaluation of molecular size by gel electrophoretic techniques. Hoppe Seylers Z. Physiol. Chem. 355(10), 1281–1290. <https://doi.org/10.1515/bchm2.1974.355.2.1281>
8. Garcion, E., Nataf, S., Berod, A., Darcy, F., Brachet, P. (1997) 1,25-dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res. Mol. Brain Res. 45(2), 255–267. <https://doi.org/10.1016/S0169-328X(96)00260-4>
9. Garcion, E., Sindji, L., Montero-Menei, C., Andre, C., Brachet, P., Darcy, F. (1998) Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 22(3), 282–294. <https://doi.org/10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7>
10. Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F., Wion, D. (2002) New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13(3), 100–105. <https://doi.org/10.1016/S1043-2760(01)00547-1>
11. Giovannoni, G. (2006) Multiple sclerosis cerebrospinal fluid biomarkers. Dis. Markers 22(4), 187–196. <https://doi.org/10.1155/2006/509476> <PubMed>
12. Gomme, P. T., Bertolini, J. (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 22(7), 340–345. <https://doi.org/10.1016/j.tibtech.2004.05.001>
13. Holick, M. F. (2009) Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 19(2), 73–78. <https://doi.org/10.1016/j.annepidem.2007.12.001> <PubMed>
14. Holmøy, T., Kampman, M. T. (2010) Alaska, multiple sclerosis, and the vitamin D hypothesis. J. Neurol. 257(2), 305–306. <https://doi.org/10.1007/s00415-009-5360-7>
15. Holmøy, T., Moen, S. M., Gundersen, T. A., Holick, M. F., Fainardi, E., Castellazzi, M., Casetta, I. (2009) 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult. Scler. 15(11), 1280–1285. <https://doi.org/10.1177/1352458509107008>
16. Kampman, M. T., Steffensen, L. H. (2010). The role of vitamin D in multiple sclerosis. J. Photochem. Photobiol. B 101(2), 137–141. <https://doi.org/10.1016/j.jphotobiol.2010.04.003>
17. Knippenberg, S., Smolders, J., Thewissen, M., Peelen, E., Tervaert, J. W., Hupperts, R., Damoiseaux, J. (2011) Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. Mult. Scler. 17(12), 1418–1423. <https://doi.org/10.1177/1352458511412655>
18. Kurtzke, J. F. (2000) Multiple sclerosis in time and space – geographic clues to cause. J. Neurovirol. 6, S134–S140 (Suppl. 2).
19. Lysandropoulos, A. P., Jaquiéry, E., Jilek, S., Pantaleo, G., Schluep, M., Du Pasquier, R. A. (2011) Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. J. Neuroimmunol. 233(1–2), 240–244. <https://doi.org/10.1016/j.jneuroim.2010.11.008>
20. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B. Y., Wolinsky, J. S. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50(1), 121–127. <https://doi.org/10.1002/ana.1032>
21. Munger, K. L., Ascherio, A. (2011) Prevention and treatment of MS: studying the effects of vitamin D. Mult. Scler. 17(12), 1405–1411. <https://doi.org/10.1177/1352458511425366> <PubMed>
22. Munger, K. L., Zhang, S. M., O’Reilly, E., Hernán, M. A., Olek, M. J., Willett, W. C., Ascherio, A. (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1), 60–65. <https://doi.org/10.1212/01.WNL.0000101723.79681.38>
23. Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., Ascherio, A. (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23), 2832–2838. <https://doi.org/10.1001/jama.296.23.2832>
24. Naveilhan, P., Neveu, I., Wion, D., Brachet, P. (1996) 1,25-dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7(13), 2171–2175. <https://doi.org/10.1097/00001756-199609020-00023>
25. Neveu, I., Naveilhan, P., Baudet, C., Brachet, P., Metsis, M. (1994) 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport 6(1), 124–126. <https://doi.org/10.1097/00001756-199412300-00032>
26. Ozgocmen, S., Bulut, S., Ilhan, N., Gulkesen, A., Ardicoglu, O., Ozkan, Y. (2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23(4), 309–313. <https://doi.org/10.1007/s00774-005-0604-9>
27. Pardridge, W. M., Sakiyama, R., Coty, W. A. (1985) Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. J. Neurochem. 44(4), 1138–1141. <https://doi.org/10.1111/j.1471-4159.1985.tb08735.x>
28. Pierrot-Deseilligny, C. (2009) Clinical implications of a possible role of vitamin D in multiple sclerosis. J. Neurol. 256(9), 1468–1479. <https://doi.org/10.1007/s00415-009-5139-x> <PubMed>
29. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O’Connor, P. W., Sandberg-Wollheim, M., Thompson, A. J., Weinshenker, B. G., Wolinsky, J. S. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 58(6), 840–846. <https://doi.org/10.1002/ana.20703>
30. Qin, Z., Qin, Y., Liu, S. (2009) Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell. Mol. Neurobiol. 29(2), 203–210. <https://doi.org/10.1007/s10571-008-9312-z>
31. Smolders, J., Damoiseaux, J., Menheere, P., Hupperts, R. (2008) Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 194(1–2), 7–17. <https://doi.org/10.1016/j.jneuroim.2007.11.014>
32. Sotgiu, S., Pugliatti, M., Sotgiu, M. A., Fois, M. L., Arru, G., Sanna, A., Rosati, G. (2006) Seasonal fluctuation of multiple sclerosis births in Sardinia. J. Neurol. 253(1), 38–44. <https://doi.org/10.1007/s00415-005-0917-6>
33. Tajouri, L., Ovcaric, M., Curtain, R., Johnson, M. P., Griffiths, L. R., Csurhes, P., Pender, M. P., Lea, R. A. (2005) Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J. Neurogenet. 19(1), 25–38. <https://doi.org/10.1080/01677060590949692>
34. Tumani, H., Hartung, H. P., Hemmer, B., Teunissen, C., Deisenhammer, F., Giovannoni, G., Zettl, U. K.; BioMS Study Group (2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 35(2), 117–127. <https://doi.org/10.1016/j.nbd.2009.04.010>
35. Wion, D., MacGrogan, D., Neveu, I., Jehan, F., Houlgatte, R., Brachet, P. (1991) 1,25-dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 28(1), 110–114. <https://doi.org/10.1002/jnr.490280111>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive